Search results for " Patient Selection"

showing 5 items of 15 documents

How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire.

2008

We used a CAPSIT-based questionnaire to estimate the percentage of parkinsonian patients suitable for subthalamic nucleus (STN) deep brain stimulation (DBS) in a movement disorders clinic. We found that out of 641 consecutive PD patients only 1.6% fulfilled strict STN-DBS criteria. When we applied more flexible criteria, the percentage of eligibility increased to 4.5%. Most patients (60%) were ineligible because they did not satisfy multiple questionnaire items. Items related to disease severity were responsible for the largest number of exclusions. This knowledge will help make decisions on resource allocation in centres wishing to start DBS surgery.

AdultMalemedicine.medical_specialtyParkinson's diseaseMovement disordersNeurologyDeep brain stimulationDeep Brain Stimulationmedicine.medical_treatmentParkinson Desease Deep Brain StimulationAudiologybehavioral disciplines and activitiesDisease severityParkinsonian DisordersSubthalamic NucleusSurveys and QuestionnairesmedicineHumansAgedChi-Square Distributionbusiness.industryPatient SelectionMiddle Agedmedicine.diseasenervous system diseasesSubthalamic nucleussurgical procedures operativenervous systemNeurologyCAPSIT; Parkinson's disease; Questionnaire; STN DBS; Adult; Aged; Chi-Square Distribution; Deep Brain Stimulation; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Subthalamic Nucleus; Surveys and Questionnaires; Patient Selection; Aging; Neurology (clinical); NeurologyPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomGeriatrics and GerontologyPsychologybusinesstherapeuticsNeuroscienceNeurology; Geriatrics and Gerontology; Neurology (clinical)
researchProduct

Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies

2015

Patients affected with intra-thoracic recurrences of primary or secondary lung malignancies after a first course of definitive radiotherapy have limited therapeutic options, and they are often treated with a palliative intent. Re-irradiation with stereotactic ablative radiotherapy (SABR) represents an appealing approach, due to the optimized dose distribution that allows for high-dose delivery with better sparing of organs at risk. This strategy has the goal of long-term control and even cure. Aim of this review is to report and discuss published data on re-irradiation with SABR in terms of efficacy and toxicity. Results indicate that thoracic re-irradiation may offer satisfactory disease c…

ThoraxRe-Irradiationmedicine.medical_specialtyLung NeoplasmsStereotactic body radiotherapymedicine.medical_treatmentLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapseLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapse; Humans; Lung Neoplasms; Patient Selection; Radiotherapy Dosage; Thorax; Radiosurgery; Oncology; Radiology Nuclear Medicine and ImagingSABR volatility modelRadiosurgeryRadiosurgeryNuclear Medicine and ImagingAblative casemedicineHumansRadiology Nuclear Medicine and imagingLung cancerThoracic relapsebusiness.industryPatient SelectionRetrospective cohort studyRadiotherapy DosageGeneral MedicineThoraxmedicine.diseaseRadiation therapyOncologyRe-irradiationRadiologyStereotactic ablative radiotherapyLung cancerbusinessRadiology
researchProduct

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

2013

A sequential approach including bortezomib induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by lenalidomide consolidation-maintenance, has been evaluated. Efficacy and safety data have been analyzed on intention-to-treat and results updated. Newly diagnosed myeloma patients 65 to 75 years of age (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (100 mg/m(2)) followed by ASCT (MEL100-ASCT), 4 cycles of lenalidomide-prednisone consolidation (LP), and lenalidomide maintenance (L) until disease progression. The complete response (CR) rate was 33% after MEL100-ASCT, 48% after LP and 53% after…

OncologyMelphalanMalemedicine.medical_specialtyImmunologyBortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients $70 years suggesting the need of a more careful patient selection.BiochemistryTransplantation AutologousDexamethasoneDisease-Free SurvivalDrug Administration SchedulePolyethylene GlycolsBortezomibAutologous stem-cell transplantationRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectLenalidomideMelphalanDexamethasoneMultiple myelomaLenalidomideAgedBortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients $70 yearsbusiness.industryBortezomibCell BiologyHematologyMiddle Agedmedicine.diseasesuggesting the need of a more careful patient selectionBoronic AcidsSurgeryThalidomideTransplantationTreatment OutcomeDoxorubicinPyrazinesDisease ProgressionFemalebusinessMultiple Myelomamedicine.drugStem Cell Transplantation
researchProduct

Monoclonal antibodies in gastrointestinal cancers

2013

Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. Areas covered: This review highlights the main biological processes implicated in gastrointestinal cancer development and progression, such as angiogenesis and epidermal growth factor receptor (EGFR) signaling pathway. On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed. Data about further monoclonal antibodies in development are also reported. Expert opinion: The use of monoclo…

OncologyVascular Endothelial Growth Factor AColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryPredictive Value of TestAntineoplastic AgentVascular Endothelial Growth Factor A; Animals; Antineoplastic Agents; Receptor Epidermal Growth Factor; Humans; Molecular Targeted Therapy; Predictive Value of Tests; Patient Selection; Antibodies Monoclonal; Genetic Testing; Individualized Medicine; Gastrointestinal Neoplasms; Tumor Markers Biological; Signal TransductionGastricDrug DiscoveryMonoclonalEpidermal growth factor receptorMolecular Targeted TherapyPrecision MedicineTumor MarkersColorectalCancerGastrointestinal NeoplasmsbiologyAntibody; Cancer; Colorectal; Gastric; Monoclonal; Animals; Antibodies Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Genetic Testing; Humans; Individualized Medicine; Molecular Targeted Therapy; Patient Selection; Predictive Value of Tests; Receptor Epidermal Growth Factor; Signal Transduction; Tumor Markers Biological; Vascular Endothelial Growth Factor A; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalIndividualized MedicineErbB ReceptorsTumor Markers BiologicalGastrointestinal NeoplasmMonoclonalGastric NeoplasmHumanReceptorSignal Transductionmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsMonoclonal antibodyAntibodiesPredictive Value of TestsInternal medicinemedicineBiomarkers TumorAnimalsHumansGastrointestinal cancerGenetic TestingAntibodyPharmacologyEpidermal Growth Factorbusiness.industryAnimalDrug Discovery3003 Pharmaceutical SciencePatient SelectionCancermedicine.diseaseBiologicalbiology.proteinReceptor Epidermal Growth Factorbusiness
researchProduct

MRI patient selection for endovascular thrombectomy in acute ischemic stroke: correlation between pretreatment diffusion weighted imaging and outcome…

2018

Introduction: Eligibility for endovascular treatment (EVT) in patients with acute ischemic stroke (AIS) depends, amongst other factors, on CT- or MR-based scores. The aim of this study was to investigate the role of Alberta Stroke Program Early CT score based on diffusion weighted imaging (MR-ASPECT) in the assessment of brain damage pre-EVT, patient selection for EVT and outcome. Materials and methods: We included in this study patients with National Institute of Health stroke score (NIHSS) at admission ≥ 8, MR-ASPECT ≥ 5 and anterior AIS, who were treated with EVT in our hospital. All patients were clinically evaluated at admission, post-EVT, discharge and at 3-month follow-up. We used MR…

Malemedicine.medical_specialtyRadiology Nuclear Medicine and Imagingmedicine.medical_treatmentDiffusion weighted imaging; Magnetic resonance; Revascularization; Stroke; Aged; Brain Ischemia; Diffusion Magnetic Resonance Imaging; Endovascular Procedures; Female; Humans; Male; Stroke; Thrombectomy; Tomography X-Ray Computed; Treatment Outcome; Patient Selection; Radiology Nuclear Medicine and ImagingRevascularizationBrain Ischemia03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineStrokeNeuroradiologyAgedThrombectomymedicine.diagnostic_testbusiness.industryCerebral infarctionPatient SelectionRevascularizationEndovascular ProceduresInterventional radiologyMagnetic resonance imagingDiffusion weighted imagingGeneral MedicineThrombolysismedicine.diseaseCollateral circulationStrokeDiffusion Magnetic Resonance ImagingTreatment OutcomeMagnetic resonanceFemaleRadiologybusinessTomography X-Ray Computed030217 neurology & neurosurgery
researchProduct